For systemic administrations of gentamicin to treat JEB, Hammersen et al. conducted a retrospective review of systemic gentamicin treatment (7.5 mg/kg daily, administered intravenously or intramuscularly for 21 days) in five infants with severe-JEB caused by p.Arg635* hotspot mutations in LAMB3 [45]. Here, LAMB3 is linked to junctional epidermolysis bullosa.